August 23, 2010Circulation156 citationsOpen Access
View Full PaperLong-Term Administration of Endothelin Receptor Antagonist Improves Coronary Endothelial Function in Patients With Early Atherosclerosis
Structured PICO
Does atrasentan improve coronary microvascular endothelial function in patients with early atherosclerosis?
P
Population
Patients with early atherosclerosis
I
Intervention
Atrasentan (endothelin receptor antagonist) for 6 months
O
Outcome
Coronary microvascular endothelial functionsurrogate
Atrasentan improves coronary microvascular endothelial function in patients with early atherosclerosis, highlighting the role of the endothelin system.
Abstract
This study demonstrates that 6-month treatment with atrasentan improves coronary microvascular endothelial function and supports the role of the endogenous endothelin system in the regulation of endothelial function in early atherosclerosis in humans. Clinical Trial Registration Information- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00271492.